Search the Newsreel

Vivo Capital LLC Buys Shares of 3,184,713 ALX Oncology Holdings Inc. $ALXO

Vivo Capital LLC recently purchased over 3.18 million shares of ALX Oncology Holdings Inc. (ALXO) for approximately $6.4 million, representing 2.37% of the company. Other institutional investors have also increased their stakes in ALXO, with institutional investors and hedge funds collectively owning 97.97% of …

Colony Bank represented at stock exchange ceremony

Colony Bank CEO Heath Fountain and First Reliance Bank CEO Rick Saunders participated in the New York Stock Exchange Closing Bell ceremony on July 27 as part of the KBW 27th Annual Summer Bank Conference. This event follows the announcement of a strategic partnership …

Cash per share of The Oncology Institute, Inc. – NASDAQ:STLN

This article focuses solely on "Cash per share of The Oncology Institute, Inc. – NASDAQ:STLN". It provides the stock symbol STLN, identifies it as being listed on the Nasdaq Stock Market, and categorizes the company under Health Services / Medical/Nursing Services. The content is …

Champions Oncology (NASDAQ:CSBR) Stock Price Crosses Below 200 Day Moving Average - Here's Why

Champions Oncology (NASDAQ:CSBR) saw its stock price fall below its 200-day moving average to $5.76, amidst a downgrade from Weiss Ratings to "sell (E+)." Despite beating quarterly earnings expectations with $0.01 EPS against an anticipated $0.05 loss and revenues of $13.84 million, the company …

Alphamab Oncology Announces Acceptance of NDA for Anbenitamab as Neoadjuvant Treatment for Her2+ Breast Cancer by the NMPA

Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of "Hold" by Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF) has received an average "Hold" recommendation from analysts, with a 12-month average price target of $7.50. The stock is currently trading near its 12-month low, and several firms have recently downgraded it. Despite the negative analyst sentiment and a missed …

The Oncology Institute, Inc. will Change its Ticker to STLN from TOI

The Oncology Institute, Inc. announced that its stock ticker symbol on the Nasdaq Capital Market will change from TOI to STLN, effective August 4, 2026. This change follows the company's recent name change to Starling Oncology, Inc.

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC

Colony Bankcorp Inc (CBAN) officer purchases 2,000 common shares

Edward G. Canup, Chief Banking Officer of Colony Bankcorp Inc (CBAN), purchased 2,000 shares of common stock on July 30, 2026, across two transactions at $21.85 and $21.75 per share. These direct holdings bring his total direct beneficial ownership to 36,701.88 shares, alongside 10,324.54 …

How Kura Oncology Inc. (KURA) Affects Rotational Strategy Timing

This article analyzes Kura Oncology Inc. (KURA) for rotational strategy timing, highlighting weak near- and mid-term sentiment but a strong long-term outlook. It details specific trading strategies, including long, breakout, and short positions, with entry points, targets, and stop losses derived from AI models. …

The Oncology Institute Changes Name to Starling Oncology

The Oncology Institute, Inc. has officially changed its name to Starling Oncology, Inc. The company, which manages community-based oncology practices across 86 clinic locations in five states, continues to provide medical oncology services, including physician services, infusion, radiation, and clinical trials. This name change …

Wells Fargo initiates Pyxis Oncology stock with overweight rating By Investing.com

Wells Fargo has initiated coverage on Pyxis Oncology Inc. (NASDAQ:PYXS) with an overweight rating and a price target of $12.00, citing the potential of its MICVO treatment for head and neck squamous cell carcinoma. Despite a recent nine percent decline, the stock has seen …

Colony Bankcorp, Inc. Revenue Breakdown – NYSE:CBAN

Colony Bankcorp, Inc. (NYSE:CBAN) generated $132.18 million in revenue last year, with its Bank segment being the top performer, contributing $112.60 million. The company's revenue primarily comes from the United States, which accounted for the entire $132.18 million in the previous year. This indicates …

Wells Fargo Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $12

Wells Fargo has initiated coverage on Pyxis Oncology (PYXS.US) with a Buy rating. The firm has set a target price of $12 for the company's stock. This initiation suggests a positive outlook from Wells Fargo regarding Pyxis Oncology's future performance.

The Oncology Institute Rebrands as Starling Oncology

The Oncology Institute (TOI), a major value-based oncology group in the U.S., has officially rebranded as Starling Oncology, Inc. The company's stock will now trade on Nasdaq under the new ticker symbol "STLN" starting August 4, 2026. This rebrand signifies the company's growth and …

Edward Canup Buys 2,000 Shares of Colony Bankcorp (NYSE:CBAN) Stock

Aktis Oncology (AKTS) Expected to Release Earnings on Monday

Price to sales forward of The Oncology Institute, Inc. – NASDAQ:TOIIW

This article provides financial information for The Oncology Institute, Inc. (NASDAQ:TOIIW) focusing on its price to sales forward metric. It appears to be a financial data page from TradingView, displaying market data, financial figures, and general company information for the stock.

Enterprise value to EBITDA forward of The Oncology Institute, Inc. – NASDAQ:TOIIW

The article provides financial information for The Oncology Institute, Inc. (NASDAQ: TOIIW), focusing on its enterprise value to EBITDA forward. It is presented within the TradingView platform, detailing financial metrics and market data related to the company.

AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share Highlights Pre-Revenue Challenges - Analyst Drop Coverage

CBAN Q2 2026 Earnings: EPS of $0.52 Tops Consensus by 7.33% - Interim Report

ALX Oncology Holdings (ALXO) Holds Steady Near $1.94 as Biotech Sector Watches Key Levels - Unusual Put Volume

Cardiff Oncology (CRDF) Holds at $0.85 After Modest Gain; Key Resistance at $0.89 in Focus - Scalping Stock Signals

Price to earnings forward of The Oncology Institute, Inc. – NASDAQ:TOIIW

The article presents financial information for The Oncology Institute, Inc. (NASDAQ: TOIIW), specifically focusing on its price-to-earnings forward metric. It appears to be a stub or a section of a larger financial data platform, providing a snapshot of the company's financial overview without detailed …

Enterprise value to EBITDA forward of Champions Oncology, Inc. – NASDAQ:CSBR

The article focuses on the "Enterprise value to EBITDA forward" financial metric for Champions Oncology, Inc. (NASDAQ: CSBR). It appears to be a financial data snippet or a specific metric page from TradingView, providing financial information for the company. The content lists various sections …

PYXS Q1 2026 Earnings: Narrow EPS Beat Fails to Stem 7.67% Share Decline - Geographic Revenue Trends

Kura Oncology, Inc. $KURA Shares Sold by Renaissance Technologies LLC

Cullinan Therapeutics (NASDAQ:CGEM) Lowered to Sell Rating by Wall Street Zen

Champions Oncology, Inc. Revenue Breakdown – NASDAQ:CSBR

Champions Oncology, Inc. (NASDAQ: CSBR) generated $59.42 million in revenue last year, primarily from its Pharmacology Services segment, which contributed $57.13 million. The majority of this revenue, $59.42 million, came from operations within the United States. This represents an increase from the previous year's …

BlackRock, Inc. Reduces Colony Bankcorp Inc (CBAN) Stake -- Shar

BlackRock, Inc. has reduced its stake in Colony Bankcorp Inc (CBAN) by selling 558,665 shares at $20.09 each, a transaction that had a 0% impact on BlackRock's overall portfolio. This move comes as CBAN's stock has seen significant appreciation and is considered modestly overvalued …

Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis

Kura Oncology Inc (KURA) has a current financial score of 6.02, indicating a weak financial status and low operating efficiency within the Biotechnology & Medical Research industry. Despite this, the company reported a year-over-year revenue increase of 29.47% and a net profit increase of …

BlackRock, Inc. Slashes Cardiff Oncology (CRDF) Stake by 78.3%

BlackRock, Inc. significantly reduced its stake in Cardiff Oncology Inc. (CRDF) by 78.32%, selling over 3.1 million shares. This move reflects BlackRock's shift away from speculative biotech ventures towards more established technology and financial services companies. Cardiff Oncology faces significant financial challenges, including unprofitability …

Should You Buy Colony Bankcorp, Inc. (NYSE:CBAN) For Its Upcoming Dividend?

Colony Bankcorp, Inc. (NYSE:CBAN) is scheduled to go ex-dividend in four days, with a payment of US$0.12 per share, representing a 2.2% trailing yield. The company's dividend appears sustainable with a modest payout ratio of 28% of profit and earnings per share growing at …

Colombier Acquisition Corp. III Revenue Breakdown – NYSE:CLBR.U

Vanguard Capital Management (CBAN) discloses 4.92% Colony Bankcorp ownership in 13G amendment

Vanguard Capital Management LLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 4.92% in Colony Bankcorp Inc (CBAN), totaling 1,042,729 shares as of June 30, 2026. The filing indicates that Vanguard has sole voting power over 136,381 shares and sole dispositive …

AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share, Yet Shares Climb 2.72% - Revenue Warning Signal